Drug Profile
Research programme: hepatitis B therapeutics - Enanta
Alternative Names: Core inhibitors - Enanta; EP-027367; HBV therapeutics - EnantaLatest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Enanta Pharmaceuticals
- Class Antivirals
- Mechanism of Action Viral core protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Hepatitis-B in USA
- 12 Apr 2018 Pharmacodynamics, safety and pharmacokinetics data from a preclinical study in Hepatitis B presented at The International Liver Congress 2018 (ILC-2018)
- 11 Apr 2018 Updated pharmacodynamics data from preclinical trials in Hepatitis B presented at The International Liver Congress 2018 (ILC-2018)